Skip to main content

Mintz Represents TRIANA Biomedicines in its Launch with $110M Funding

BOSTON – Mintz represented TRIANA Biomedicines, Inc., which today announced its launch with $110M in total funding as it exited stealth mode. TRIANA is building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. This funding provides the foundation for TRIANA to develop molecular glue drug candidates. TRIANA was originally seeded by RA Capital Management and Atlas Venture, and Lightspeed Venture Partners and the company's original seed investors, co-led the Series A investment. Pfizer Ventures, Surveyor Capital (a Citadel company) and Logos Capital also participated. Mintz has represented the company since its inception.

Lewis Geffen, Co-Chair of Mintz’s Life Sciences Practice Group and its Venture Capital & Emerging Companies Practice Groups, notes, “We’re excited for TRIANA’s launch. This is the fourth launch in a series of emerging companies whom we’ve represented in recent months coming out of RA Capital. It speaks to the confidence that investors have in the healthcare and life sciences emerging growth space and points to the further emergence of new and innovative companies to join the market.  As a law firm ingrained in the Boston life sciences ecosystem, we delight in working with companies at the cutting edge of science such as TRIANA.”

Mintz is an internationally recognized, multidisciplinary law firm with 550+ attorneys serving clients worldwide.

For more information about Mintz, please visit